File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Conference Paper: Addition of cetuximab to oxaliplatin-based chemotherapy on liver and spleen size and thrombocytopenia in patients with metastatic colorectal cancer

TitleAddition of cetuximab to oxaliplatin-based chemotherapy on liver and spleen size and thrombocytopenia in patients with metastatic colorectal cancer
Authors
KeywordsMedical sciences
Oncology
Issue Date2012
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
The 14th World Congress of the European Society for Medical Oncology (ESMO) on Gastrointestinal Cancer, Barcelona, Spain, 27–30 June 2012. In Annals of Oncology, 2012, v. 23 suppl. 4, p. iv94, abstract P-0224 How to Cite?
AbstractIntroduction: A previous retrospective study revealed that oxaliplatin could induce splenic enlargement which in turn was associated with thrombocytopenia in patients with early stage colorectal cancer. However it has not still been known whether cetuximab aggravates or alleviates such effects in patients with metastatic colorectal cancer. We performed a retrospective study to investigate the effect of addition of cetuximab to oxaliplatin-based regimen as 1st line palliative chemotherapy on liver and spleen size and its association with thrombocytopenia in patients with metastatic colorectal cancer. Methods: Ninety two consecutive patients with metastatic colorectal cancer, recruited from January 2008 to December 2011, received either oxaliplatin-based chemotherapy (XELOX or FOLFOX4, n=57) and the same regimen with cetuximab (n=35) as 1st line palliative chemotherapy for their metastatic colorectal cancer. Contrast-enhanced computed tomography (CT) scan was performed at baseline and after chemotherapy +/- cetuximab at regular intervals. The volumes of the residual liver after excluding liver metastases if present and spleen at baseline and after oxaliplatin-based chemotherapy +/- cetuximab were determined by contouring these organs in Eclipse Treatment Planning System version 8.9. Changes in volume of liver and spleen in all patients and subgroups stratified according to the use of cetuximab were compared by paired and independent sampled t-tests respectively. Binary logistic regression was performed for any factors predictive of thrombocytopenia defined as <100 x 109/l. Results: Both liver (mean increase 4.2%, p=0.029) and spleen (mean increase 36.4%, p=0.000) enlarged in all patients after the use of oxaliplatin-based chemotherapy +/- cetuximab. Use of cetuximab in addition to oxaliplatin did not aggravate or protect the liver (mean decrease 0.56% for chemotherapy alone group vs mean increase 4.71% for cetuximab group, p=0.374) or spleen (mean increase 41.0% for chemotherapy alone group vs mean increase 31.9% for cetuximab group, p=0.338) from further change in size. Cumulative dose of cetuximab correlated with platelet count (Pearson's correlation coefficient r=0.503, p=0.020) and it was also associated with thrombocytopenia (relative risk: 4.563, p=0.033). However the risk of grade 3 or above (CTCAE version 4.0) thrombocytopenia was similar between those who received cetuximab and those who did not. Conclusion: Oxaliplatin-based chemotherapy was confirmed to increase liver and spleen size in patients with metastatic colorectal cancer. Addition of cetuximab to oxaliplatin-based chemotherapy did not cause further hepatic or splenic enlargement but was associated with an increased chance of mild degree of thrombocytopenia.
DescriptionPosters: P-0224
Persistent Identifierhttp://hdl.handle.net/10722/165129
ISSN
2019 Impact Factor: 18.274
2015 SCImago Journal Rankings: 4.362
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, Ven_US
dc.contributor.authorFang, WJen_US
dc.contributor.authorLam, KOen_US
dc.contributor.authorChoi, CWen_US
dc.contributor.authorNg, Sen_US
dc.contributor.authorHo, Gen_US
dc.contributor.authorCheng, Ten_US
dc.contributor.authorLiu, RKYen_US
dc.contributor.authorLeung, TWen_US
dc.contributor.authorKwong, DLWen_US
dc.contributor.authorZheng, SSen_US
dc.date.accessioned2012-09-20T08:15:21Z-
dc.date.available2012-09-20T08:15:21Z-
dc.date.issued2012en_US
dc.identifier.citationThe 14th World Congress of the European Society for Medical Oncology (ESMO) on Gastrointestinal Cancer, Barcelona, Spain, 27–30 June 2012. In Annals of Oncology, 2012, v. 23 suppl. 4, p. iv94, abstract P-0224en_US
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/165129-
dc.descriptionPosters: P-0224-
dc.description.abstractIntroduction: A previous retrospective study revealed that oxaliplatin could induce splenic enlargement which in turn was associated with thrombocytopenia in patients with early stage colorectal cancer. However it has not still been known whether cetuximab aggravates or alleviates such effects in patients with metastatic colorectal cancer. We performed a retrospective study to investigate the effect of addition of cetuximab to oxaliplatin-based regimen as 1st line palliative chemotherapy on liver and spleen size and its association with thrombocytopenia in patients with metastatic colorectal cancer. Methods: Ninety two consecutive patients with metastatic colorectal cancer, recruited from January 2008 to December 2011, received either oxaliplatin-based chemotherapy (XELOX or FOLFOX4, n=57) and the same regimen with cetuximab (n=35) as 1st line palliative chemotherapy for their metastatic colorectal cancer. Contrast-enhanced computed tomography (CT) scan was performed at baseline and after chemotherapy +/- cetuximab at regular intervals. The volumes of the residual liver after excluding liver metastases if present and spleen at baseline and after oxaliplatin-based chemotherapy +/- cetuximab were determined by contouring these organs in Eclipse Treatment Planning System version 8.9. Changes in volume of liver and spleen in all patients and subgroups stratified according to the use of cetuximab were compared by paired and independent sampled t-tests respectively. Binary logistic regression was performed for any factors predictive of thrombocytopenia defined as <100 x 109/l. Results: Both liver (mean increase 4.2%, p=0.029) and spleen (mean increase 36.4%, p=0.000) enlarged in all patients after the use of oxaliplatin-based chemotherapy +/- cetuximab. Use of cetuximab in addition to oxaliplatin did not aggravate or protect the liver (mean decrease 0.56% for chemotherapy alone group vs mean increase 4.71% for cetuximab group, p=0.374) or spleen (mean increase 41.0% for chemotherapy alone group vs mean increase 31.9% for cetuximab group, p=0.338) from further change in size. Cumulative dose of cetuximab correlated with platelet count (Pearson's correlation coefficient r=0.503, p=0.020) and it was also associated with thrombocytopenia (relative risk: 4.563, p=0.033). However the risk of grade 3 or above (CTCAE version 4.0) thrombocytopenia was similar between those who received cetuximab and those who did not. Conclusion: Oxaliplatin-based chemotherapy was confirmed to increase liver and spleen size in patients with metastatic colorectal cancer. Addition of cetuximab to oxaliplatin-based chemotherapy did not cause further hepatic or splenic enlargement but was associated with an increased chance of mild degree of thrombocytopenia.-
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology-
dc.titleAddition of cetuximab to oxaliplatin-based chemotherapy on liver and spleen size and thrombocytopenia in patients with metastatic colorectal canceren_US
dc.typeConference_Paperen_US
dc.identifier.emailLee, V: vhflee@hku.hken_US
dc.identifier.emailLam, KO: lamkaon@hku.hken_US
dc.identifier.emailLiu, RKY: ricoliu@hkucc.hku.hken_US
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hken_US
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_US
dc.identifier.authorityLee, V=rp00264en_US
dc.identifier.authorityLam, KO=rp01501en_US
dc.identifier.authorityKwong, DLW=rp00414en_US
dc.description.natureabstract-
dc.identifier.doi10.1016/S0923-7534(20)30150-2-
dc.identifier.hkuros206044en_US
dc.identifier.hkuros227944-
dc.identifier.volume23en_US
dc.identifier.issuesuppl. 4-
dc.identifier.spageiv94, abstract P-0224en_US
dc.identifier.epageiv94, abstract P-0224en_US
dc.identifier.isiWOS:000305826900281-
dc.publisher.placeUnited Kingdom-
dc.customcontrol.immutablesml 140206-
dc.identifier.issnl0923-7534-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats